Otonomy Inc (OTIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Aug 01, 2022: Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
Jul 25, 2022: Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022: Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear. The company’s Otiprio is US FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients and otitis externa. Its pipeline portfolio encompasses Otividex for the treatment of meniere’s disease; OTO-313 for the treatment of tinnitus; OTO-510 for the treatment of cisplatin-induced hearing loss; OTO-413 for the treatment of synaptopathy hearing loss; and OTO-6XX for the treatment of severe hearing loss. The company is also investigating a preclinical program on GJB2 gener therapy in collaboration with AGTC for the treatment of congenital hearing loss. It employs its proprietary formulation technology that uses a thermosensitive gel and drug microparticles for enabling single-dose treatment by a physician. Otonomy is headquartered in San Diego, California, the US.Otonomy Inc Key Recent Developments
Nov 10, 2022: Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateAug 01, 2022: Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
Jul 25, 2022: Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022: Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company- Otonomy Inc - Key Facts
- Otonomy Inc - Key Employees
- Otonomy Inc - Key Employee Biographies
- Otonomy Inc - Major Products and Services
- Otonomy Inc - History
- Otonomy Inc - Company Statement
- Otonomy Inc - Locations And Subsidiaries
- Head Office
- Company Overview
- Otonomy Inc - Business Description
- R&D Overview
- Otonomy Inc - Corporate Strategy
- Otonomy Inc - SWOT Analysis
- SWOT Analysis - Overview
- Otonomy Inc - Strengths
- Otonomy Inc - Weaknesses
- Otonomy Inc - Opportunities
- Otonomy Inc - Threats
- Otonomy Inc - Key Competitors
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- Otonomy Inc, Recent Deals Summary
- Nov 10, 2022: Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Aug 01, 2022: Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
- Jul 25, 2022: Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- May 12, 2022: Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
- Mar 15, 2022: Otonomy to Host Virtual Investor R&D Event on March 22, 2022
- Feb 28, 2022: Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Feb 25, 2022: Otonomy to Host Virtual Investor R&D Event on March 22, 2022
- Feb 16, 2022: Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting
- Jan 25, 2022: Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
- Jan 06, 2022: Otonomy reports corporate and product pipeline update
- Methodology
- Ratio Definitions
- About the Publisher
- Contact the Publisher
- Disclaimer
- Otonomy Inc, Key Facts
- Otonomy Inc, Key Employees
- Otonomy Inc, Key Employee Biographies
- Otonomy Inc, Major Products and Services
- Otonomy Inc, History
- Otonomy Inc, Key Competitors
- Otonomy Inc, Ratios based on current share price
- Otonomy Inc, Annual Ratios
- Otonomy Inc, Interim Ratios
- Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- Otonomy Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- Otonomy Inc, Performance Chart (2017 - 2021)
- Otonomy Inc, Ratio Charts
- Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Otonomy Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Sound Pharmaceuticals Inc
- Sensorion SA
- Fennec Pharmaceuticals Inc
- Decibel Therapeutics Inc
- Autifony Therapeutics Ltd
- Audion Therapeutics BV
- Altamira Therapeutics Ltd
